Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Approaches to chronic kidney disease : a guide for primary care providers and non-nephrologists / / Jerry McCauley, Seyed Mehrdad Hamrahian, Omar H. Maarouf, editors
| Approaches to chronic kidney disease : a guide for primary care providers and non-nephrologists / / Jerry McCauley, Seyed Mehrdad Hamrahian, Omar H. Maarouf, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (448 pages) |
| Disciplina | 616.61 |
| Soggetto topico |
Kidneys - Diseases
Malalties del ronyó Malalties cròniques |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-83082-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Acknowledgments -- Contents -- Contributors -- Chapter 1: Renal Physiology for Primary Care Clinicians -- Introduction -- Vascular Structure of the Kidney -- Glomerular Filtration Rate (GFR) -- Renal Tubular Function -- Proximal Tubular Segments -- Loop of Henle -- Distal Tubular Segments -- Collecting Tubules -- References -- Chapter 2: State of the Care, Definition, and Epidemiology of Chronic Kidney Disease -- Definition of Chronic Kidney Disease -- Significance of Chronic Kidney Disease -- Economic Burden of Chronic Kidney Disease -- Common Causes of ESRD -- Epidemiology/Prevalence of Chronic Kidney Disease -- Risk Factors for CKD and CKD Prevalence -- Awareness of CKD -- Prevention and Screening -- Screening -- Slowing the Progression of CKD -- Summary -- References -- Chapter 3: Screening Tests for CKD Detection -- Introduction -- Urinalysis -- Urine Specimen Collection -- Gross Examination -- Urine Dipstick -- Urine Sediment -- Glomerular Filtration Rate and Its Assessment -- Assessment of GFR -- Measurement of GFR -- Estimation of GFR -- Creatinine as a Marker to Estimate GFR -- Creatinine Clearance -- Equations for Estimating GFR from Serum Creatinine -- Cockcroft-Gault Formula -- MDRD Study Equation -- CKD-EPI Equation -- Urea as a Marker for GFR -- Serum Cystatin C -- GFR Assessment in Circumstances Requiring High Degree of Accuracy -- Kidney Donor Evaluation -- Drug Dosing -- Assessing Kidney Function Beyond eGFR -- Disease Duration -- Major Causes and Classification of Kidney Disease -- Proteinuria -- Albuminuria -- Measurement of Total Urine Protein Excretion -- Approach to Patient with Proteinuria -- Hematuria -- Radiologic Assessment in Renal Disease -- Ultrasound -- Computed Tomography (CT) -- Magnetic Resonance Imaging -- Abdominal Radiography -- Renal Arteriography -- Radionuclide Studies.
Retrograde or Anterograde Pyelography -- Renal Biopsy -- Indications of Renal Biopsy -- Contraindications -- Pre-biopsy Work-Up -- Complications -- References -- Chapter 4: Slowing Chronic Kidney Disease Progression -- Introduction -- CKD Detection -- Slowing CKD Progression by Optimizing Hypertension Control -- Slowing CKD Progression by Reducing Proteinuria -- Slowing Diabetic Kidney Disease -- Slowing CKD Progression in Cardiovascular Disease -- Slowing CKD Progression by Optimizing Metabolic Acidosis -- Hyperlipidemia -- Hyperuricemia -- Obesity and CKD Progression -- Smoking -- New Therapies Targeting Renal Fibrosis to Slow CKD Progression -- Conclusion -- References -- Chapter 5: Progression of CKD and Uremic Symptoms -- Definition of Chronic Kidney Disease (CKD) -- Clinical Presentation -- Things to Include in Routine History and Physical in a Patient with CKD -- Making Use of Existing Laboratory Data and Imaging Studies -- CKD and Its Risk Factors -- Etiology of CKD -- Stages of CKD and Its Progression -- CKD and Its Progression -- Definition of CKD Progression and Its Assessment -- Disclosing to Patients -- Referral to a Nephrologist -- Natural History of Renal Disease -- Pathophysiology of CKD and Its Progression -- Factors to Predict the Progression of CKD -- Intraglomerular Hypertension and Glomerular Hypertrophy -- Proteinuria -- Tubulointerstitial Fibrosis -- Diabetes Mellitus and CKD -- Metabolic Acidosis -- Uric Acid -- Use of Smoking and Illicit Drugs -- Interaction with Healthcare Professionals -- Taking a Charge of Own Health -- Socioeconomic Impact -- APOL1 Genotype in African Americans (AA) -- CKD Manifestations and Their Management -- Uremia -- Pathogenesis of Uremia -- Signs and Symptoms of Uremia -- Approach to Management of Uremia -- Conclusion -- References -- Chapter 6: Diabetic Kidney Disease -- Introduction. Pathogenesis -- Incidence and Prevalence -- Risk Factors -- Age -- Race/Ethnicity -- Obesity -- Uncontrolled Blood Sugar -- Hypertension -- Albuminuria -- Role of Kidney Biopsy -- Pathology -- Progression -- Treatment -- Following DKD Patient During Treatment to Control CV Risk Factors -- References -- Chapter 7: Hypertensive Kidney Disease -- Introduction and Epidemiology -- Definitions -- Epidemiology of Hypertensive Kidney Disease -- Causes of Hypertensive Kidney Disease -- Impaired Sodium Excretion -- Renin-Angiotensin-Aldosterone System -- Sympathetic Nervous System -- Impaired Renal Autoregulation in CKD -- Inflammation -- BP Target in Hypertensive Kidney Disease -- Blood Pressure Monitoring and Blood Pressure Patterns in Hypertensive Kidney Disease -- Masked Hypertension in CKD -- Resistant Hypertension in Hypertensive Kidney Disease -- Role of Hypertension in the Progression of CKD -- Treatment of Hypertensive Kidney Disease -- Use of RAAS Inhibition in CKD -- Diuretics -- Aldosterone Antagonists in Hypertensive Kidney Disease -- Dietary Potassium Supplementation -- SGLT-2 Inhibitors -- Allopurinol -- Aspirin and Clopidogrel -- Weight Loss for Treatment of Hypertensive Kidney Disease -- Evaluation for Renal Artery Stenosis in Hypertensive Kidney Disease -- Hypertensive Emergency in Hypertensive Kidney Disease -- Prognosis -- References -- Chapter 8: Infection-Related Kidney Disease -- Introduction -- Virus-Induced Kidney Disease -- Human Immunodeficiency Virus (HIV) -- Human Immunodeficiency Virus-Associated Nephropathy (HIVAN) -- APOL1 Gene -- HIV-Associated Immune Complex Kidney Disease (HIVICK) -- Treatment of HIV with HIV-Associated Anti-Retro-Viral Therapy (HAART) -- Protease Inhibitors (PI) -- Nucleotide Reverse Transcriptase Inhibitors (NRTI) -- Non-nucleotide Reverse Transcriptase Inhibitors (NNRTI) -- Hepatitis C Virus (HCV). HCV Treatment -- Hepatitis B Virus -- HBV Treatment -- Hepatitis E Virus -- Other Virus-Associated Renal Disease -- Flaviviruses -- Dengue Virus -- Hantavirus -- Coronavirus-19 -- Bacterial Infections -- Post-streptococcal Glomerulonephritis -- Infection-Related Glomerulonephritis -- Mycobacterial Infections -- Fungal Infections -- Protozoan and Parasitic Infections -- Malaria -- Leptospirosis -- Leishmaniasis -- Schistosomiasis -- Filariasis -- Conclusion -- References -- Chapter 9: Hepatorenal Syndrome -- Epidemiology -- Pathophysiology of HRS -- HRS-AKI -- HRS-NAKI -- Clinical Manifestations -- Diagnosis -- Differential Diagnosis -- Treatment -- Medical Management -- TIPS -- Renal Replacement Therapy -- Liver Transplantation -- Prevention -- Prognosis -- References -- Chapter 10: Lupus Nephritis -- Introduction -- Pathophysiology -- Diagnosis -- Treatment -- Clinical Response Definitions -- Treatment Protocols (Please See Table 10.1 for a Summary) -- Induction Therapy -- Maintenance Therapy -- Emerging Therapies and Protocols -- Antimalarials in LN -- B-cell Depletion -- Management of Class V LN -- Pregnancy and LN -- Dialysis and Transplantation in LN -- Conclusion -- References -- Chapter 11: Onconephrology -- Introduction -- Assessment of Kidney Function in Cancer Patients -- Acute Kidney Injury in Cancer Patients -- Tumor Lysis Syndrome -- Therapy-Related Acute Kidney Injury -- Traditional Chemotherapeutic Agents -- Platinum Salts -- Methotrexate and Pemetrexed -- Ifosfamide and Cyclophosphamide -- Nitrosoureas -- Gemcitabine and Mitomycin C -- Targeted Therapy -- Vascular Endothelial Growth Factor (VEGF) Inhibitors -- BRAF Inhibitors -- Anaplastic Lymphoma Kinase (ALK) Inhibitors -- Proteasome Inhibitors -- Immunotherapy -- Immune Checkpoint Inhibitors (ICPI) -- Chimeric Antigen Receptor T-Cell (CAR-T) Therapy -- Radiation Nephropathy. Hematopoietic Stem Cell Transplantation (HSCT) -- Cancer-Related Kidney Disease -- Paraprotein-Related Kidney Disease -- Classification of Paraprotein-Related Diseases -- Clinical and Histological Manifestations of Renal Involvement in Plasma Cell Dyscrasias -- Multiple Myeloma -- Evaluation of Suspected Monoclonal Gammopathy -- Treatment of Monoclonal Gammopathies with Renal Involvement -- Leukemia and Lymphoma -- Paraneoplastic Glomerular Disease -- Urinary Tract Obstruction -- Renal Cell Carcinoma -- CKD, ESRD, and Cancer -- References -- Chapter 12: Complications of Chronic Kidney Disease: Electrolyte and Acid-Base Disorders -- Acidemia of Chronic Kidney Disease -- Epidemiology -- Pathophysiology -- Clinical Findings -- Adverse Effects -- Treatment -- Available Therapeutics -- Calculation of Bicarbonate Deficit -- Dietary Management of Metabolic Acidosis of Chronic Kidney Disease -- Pharmaceutical Management -- Sodium Disorder and Chronic Kidney Disease -- Epidemiology -- Pathophysiology of Concentrating and Diluting Defects in Chronic Kidney Disease -- The Counter-Current Mechanism in Chronic Kidney Disease -- Clinical Implications -- Treatment -- Hypovolemic Hyponatremia Secondary to Volume Deficits -- Euvolemic/Hypervolemic Hyponatremia -- ADH Inhibitors -- Water Restriction -- Use of Loop Diuretics -- Hypernatremia and Chronic Kidney Disease -- Hyponatremia and End-Stage Renal Disease -- Potassium and Chronic Kidney Disease -- Epidemiology -- Hyperkalemia in Chronic Kidney Disease -- Mechanism of Hyperkalemia and Chronic Kidney Disease -- Clinical Sequel -- Treatment -- Sodium Polystyrene Sulfonate -- Calcium Polystyrene Sulfonate -- Patiromer -- Sodium Zirconium Cyclosilicate -- Renal Replacement Therapy -- Hypokalemia in Chronic Kidney Disease -- Clinical Sequel -- Goals of Treatment -- Potassium Preparation -- References. Chapter 13: Anemia in Chronic Kidney Disease. |
| Record Nr. | UNINA-9910523898503321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Behavioral clinical trials for chronic diseases : scientific foundations / / Lynda H. Powell, Kenneth E. Freedland, Peter G. Kaufmann
| Behavioral clinical trials for chronic diseases : scientific foundations / / Lynda H. Powell, Kenneth E. Freedland, Peter G. Kaufmann |
| Autore | Powell Lynda H. |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (324 pages) |
| Disciplina | 616.044 |
| Soggetto topico |
Chronic diseases
Behavior therapy - Research Chronic diseases - Treatment - Research Malalties cròniques Teràpia de la conducta Investigació mèdica Assaigs clínics |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-39330-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910502589503321 |
Powell Lynda H.
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiac considerations in chronic lung disease / / edited by Surya P. Bhatt
| Cardiac considerations in chronic lung disease / / edited by Surya P. Bhatt |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2020 |
| Descrizione fisica | 1 online resource (xi, 272 pages) : illustrations |
| Disciplina | 616.12 |
| Collana | Respiratory Medicine |
| Soggetto topico |
Cardiopulmonary system - Diseases
Lungs - Diseases - Complications Chronic diseases Cardiovascular Physiological Phenomena Lung Chronic Disease Cardiovascular System Cardiology Sistema cardiovascular Malalties del pulmó Malalties cròniques Cardiologia Medicina intensiva |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-43435-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Epidemiology of CLD and CVD -- Origins of Cardiopulmonay Disease in Early Life -- Gender Differences -- Genetics -- Physiology: Heart-Lung Interactions -- Pathophysiology of Coronary Artery Disease in CLD -- Pathophysiology of Heart Failure in CLD -- Pathophysiology of Right Heart Disease in CLD -- Extracardiac Cardiovascular Disease: Cerebrovascular Disease, Peripheral Arterial Disease -- Clinical Manifestations and Diagnosis -- Imaging -- Functional Evaluation: Cardiopulmonary Exercise Testing -- Prognosis: Impact of CVD on CLD and CLD on CVD -- Therapy and Medication Interactions -- Acute Exacerbations -- Lung Transplantation -- Future Perspectives. |
| Record Nr. | UNINA-9910407729403321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Chronic diseases and injuries in Canada
| Chronic diseases and injuries in Canada |
| Pubbl/distr/stampa | Ottawa, : Public Health Agency of Canada |
| Disciplina | 614.4 |
| Soggetto topico |
Chronic diseases - Canada
Wounds and injuries - Canada Maladies chroniques - Canada Lésions et blessures - Canada Chronic diseases Wounds and injuries Ferides i lesions Malalties cròniques Epidemiologia |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. Revistes electròniques. |
| ISSN | 1925-6523 |
| Classificazione |
cci1icc
coll11 coll14 coll20 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910139347003321 |
| Ottawa, : Public Health Agency of Canada | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Chronic Lung Diseases : Pathophysiology and Therapeutics / / edited by Sheikh Rayees, Inshah Din, Gurdarshan Singh, Fayaz A Malik
| Chronic Lung Diseases : Pathophysiology and Therapeutics / / edited by Sheikh Rayees, Inshah Din, Gurdarshan Singh, Fayaz A Malik |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (VIII, 180 p. 6 illus., 4 illus. in color.) |
| Disciplina | 780 |
| Soggetto topico |
Medicine
Biomedicine, general Malalties del pulmó Malalties cròniques |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-3734-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1 -- Therapeutic Advances in the Management of Pulmonary Arterial Hypertension -- Chapter 2 -- Asthma: Pathophysiology, Current Status and Therapeutics -- Chapter 3 -- Cystic Fibrosis: Biology and Therapeutics -- Chapter 4 -- Chronic Pneumonia -- Chapter 5 -- Tuberculosis -- Chapter 6 -- Lung cancer – Pathophysiology and Current Advancements in Therapeutics -- Chapter 7 -- Acute Respiratory Distress Syndrome – Therapeutics, Pathobiology and Prognosis -- Chapter 8 -- Chronic Obstructive Pulmonary Disease - An Update on Therapeutics and Pathophysiological Understanding. . |
| Record Nr. | UNINA-9910416106303321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Chronicity : treating and coping / / Dagmar Rinnenburger
| Chronicity : treating and coping / / Dagmar Rinnenburger |
| Autore | Rinnenburger Dagmar |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (XIX, 122 p. 18 illus., 14 illus. in color.) |
| Disciplina | 616.044 |
| Soggetto topico |
Chronic diseases - Treatment
Chronically ill - Services for Malalties cròniques Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-66873-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Stories from a world where everyone can enter, and where many already reside -- Chronic / Acute: two opposite scenarios? -- The burden on chronicity -- The strain of being chronically ill -- The strain of treating chronic patients -- How to treat the sick and, above all, where? -- The rainbow of places of care disrupted by the COVID-19 pandemic -- The epidemiological shift from acute to chronic in India -- Asthma can be lethal (but it is also possible to live with it) -- Education as therapy: a history of failure? -- Primary care, incremental care and initiative anticipatory healthcare -- Chronic meets chronic (when doctors are dangerous) -- Chronic seeks chronic: the opportunities of Web 2.0 -- The decline of chronic illness towards the end of life -- If chronic illness works with palliative care -- In the spotlight or behind the scenes? -- In conclusion. . |
| Record Nr. | UNINA-9910484930203321 |
|
Rinnenburger Dagmar
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Dementia and Chronic Disease : Management of Comorbid Medical Conditions / / edited by Angela Georgia Catic
| Dementia and Chronic Disease : Management of Comorbid Medical Conditions / / edited by Angela Georgia Catic |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (ix, 241 pages) : illustrations |
| Disciplina | 616.83 |
| Soggetto topico |
Geriatrics
General practice (Medicine) Public health Geriatrics/Gerontology General Practice / Family Medicine Public Health Demència Malalties cròniques Geriatria |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-46398-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Dementia and Chronic Disease in the Elderly -- Management of Physical Function in Older Adults with Dementia -- Management of Cognitive Function in Older Adults with Dementia -- Medication Management In Older Adults with Dementia -- Management of Heart Failure in Older Adults with Dementia -- Type 2 Diabetes Mellitus Management in Older Adults with Dementia -- COPD Management in Older Adults with Dementia -- CKD in Older Adults with Dementia -- Management of Musculoskeletal Pain in Older Adults with dementia -- Management of Sleep Issues in Older Adults with Dementia -- Visual Issues in Older Adults with Dementia -- Skin Conditions in Older Adults with Dementia -- Oral Health in Older Adults with Dementia -- Health Maintenance and Preventive Care in Older Adults with Dementia. |
| Record Nr. | UNINA-9910407729003321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Exercise, autophagy and chronic diseases / / Ning Chen, editor
| Exercise, autophagy and chronic diseases / / Ning Chen, editor |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (267 pages) |
| Disciplina | 617.1027 |
| Soggetto topico |
Sports medicine
Autofàgia Malalties cròniques Exercici |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-16-4525-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Acknowledgments -- Contents -- Chapter 1: Molecular Processes and Regulation of Autophagy -- 1 Introduction -- 2 Molecular Mechanism of Autophagy: A Historical Interest -- 3 The Molecular Mechanisms of Autophagy in Mammals -- 3.1 Autophagy Induction -- 3.2 Autophagosome Formation -- 3.3 Fusion Between Autophagosome and Lysosome -- 4 Molecular Regulation of Autophagy Machinery -- 4.1 The mTOR-Dependent Signaling Pathway -- 4.2 mTOR-Independent Signaling Pathways -- 4.2.1 Calcium Signaling in Autophagy -- 4.2.2 Calcium-Releasing Channel Control in Autophagy Mediated by TRPML -- 4.2.3 The mTOR-Independent TRPML1 Channel -- 4.2.4 The Regulation of Autophagy Via miRNA, ROS, and JNK-Beclin1 -- 5 Conclusion -- References -- Chapter 2: Acute and Chronic Exercise on Autophagy -- 1 Introduction -- 2 Exercise and Autophagy -- 2.1 Effect of Exercise on Skeletal Muscle Autophagy -- 2.2 Effect of Exercise on Myocardial Autophagy -- 2.3 Effect of Exercise on the Regulation of Autophagy Level in Hepatocytes -- 2.4 Effect of Exercise on Brain Function -- 3 Acute Exercise-Induced Autophagy -- 3.1 Underlying Mechanism for the Effect of Acute Exercise on Skeletal Muscle Autophagy -- 3.2 Underlying Mechanism for the Effect of Acute Exercise on Myocardial Autophagy -- 4 Chronic Exercise Induces Autophagy -- 4.1 Underlying Mechanism for the Effect of Chronic Exercise on Skeletal Muscle Autophagy -- 4.2 Underlying Mechanism for the Effect of Chronic Exercise on Myocardial Autophagy -- 5 Conclusion and Prospects -- References -- Chapter 3: The Beneficial Roles of Exercise-Mediated Autophagy in T2DM -- 1 The Background of T2DM -- 2 Autophagy in Insulin Target Tissues of T2DM -- 2.1 Hepatic Autophagy in T2DM -- 2.2 Adipose Autophagy in T2DM -- 2.3 Skeletal Muscle Autophagy in T2DM -- 2.4 Pancreatic β-Cell Autophagy in T2DM.
3 Exercise-Mediated Autophagy in T2DM -- 3.1 Exercise-Mediated Autophagy Improves Insulin Sensitivity in T2DM -- 3.2 Exercise-Mediated Autophagy Maintains Mitochondrial Quality Control in T2DM -- 3.3 Exercise-Mediated Autophagy Maintains Muscle Mass and Function in T2DM -- 4 Conclusion -- References -- Chapter 4: Exercise-Induced Autophagy and Obesity -- 1 Introduction -- 2 General Characteristics and Mechanism of Autophagy -- 3 Relationship Between Autophagy and Obesity -- 3.1 Lipophagy and Obesity -- 3.2 Mitophagy and Obesity -- 3.3 Reticulophagy and Obesity -- 4 The Effect of Exercise-Induced Autophagy on Obesity -- 4.1 Endurance Exercise -- 4.2 Resistance Exercise or Combined Endurance Exercise -- 5 Exercise Interventions for Obese Patients Targeting Autophagy -- 6 Conclusion -- References -- Chapter 5: Exercise-Mediated Autophagy and Nonalcoholic Fatty Liver Disease -- 1 Introduction -- 1.1 Epidemiology and Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) -- 1.2 Pathological Process of NAFLD -- 1.3 Autophagy in NAFLD -- 1.3.1 Autophagy Regulates Lipid Storage in Hepatocytes -- 1.3.2 Autophagy Regulates the Differentiation and Production of Adipocytes -- 2 Effect of Exercise Intervention in NAFLD and Underlying Mechanisms -- 2.1 Exercise Increases Lipid Metabolism Via Regulation of Autophagy -- 2.2 Exercise Alleviates NAFLD by Reducing Mitochondrial Oxidative Stress -- 2.3 Exercise Regulates microRNA-Mediated Autophagy in NAFLD -- 2.4 Exercise Promotes Autophagy in NAFLD by Increasing H2S Activity -- 2.5 Exercise-Mediated Autophagy Regulates Liver Fibrosis and Late-Stage NAFLD -- 3 Weight Loss Is a Feasible Strategy for NAFLD? -- 4 Exercise Prescriptions -- 5 Conclusion and Future Perspectives -- References -- Chapter 6: Exercise-Mediated Autophagy and Brain Aging -- 1 Autophagy in the Aging Process. 1.1 Autophagy Protects Against Metabolic Stress -- 1.2 Autophagy Acts as a Cell Housekeeper -- 1.3 Autophagy as a Genome Guardian -- 2 Autophagy Regulators During Aging Process -- 2.1 mTOR -- 2.2 Sirtuin (SIRT1) -- 2.3 p53 -- 3 Brain Aging -- 3.1 Characteristics of Brain Aging -- 3.1.1 Cell Senescence -- 3.1.2 Accumulation of Damaged Cellular Contents -- 3.1.3 Structural Changes in Brain During Aging Process -- 3.2 Underlying Mechanisms of Brain Aging -- 3.3 Brain Aging and Neurodegenerative Diseases -- 4 Exercise-Induced Autophagy and Brain Aging -- 4.1 Exercise and Brain Aging in Basic Research -- 4.1.1 Autophagy -- 4.1.2 Mitochondria -- 4.1.3 Inflammation -- 4.1.4 DNA Repairing -- 4.1.5 Lifespan Extension -- 4.2 Exercise and Brain Aging in Clinical Research -- 4.2.1 Brain Volume -- 4.2.2 Cognitive Capacity -- 5 Outlook and Prospects -- References -- Chapter 7: Exercise-Mediated Autophagy and Alzheimer´s Disease -- 1 The Epidemiology of AD -- 2 The Pathogenesis of AD -- 2.1 Amyloid Cascade Hypothesis -- 2.2 Tau Protein Hyperphosphorylation -- 2.3 Neuroinflammation -- 2.4 Mitophagy Dysfunction -- 2.5 Cholinergic Neurotransmitter Pathway Abnormalities -- 3 Autophagy and AD -- 3.1 Autophagy -- 3.2 The Regulatory Role of Autophagy in AD -- 3.2.1 Autophagy and Aβ -- 3.2.2 Autophagy and Tau Protein -- 3.2.3 Autophagy and Neuroinflammation -- 4 Exercise-Induced Autophagy in AD -- 4.1 Exercise Can Improve the Level of Autophagy -- 4.1.1 Exercise Can Increase the Autophagy Level of Normal Brain Cells -- 4.1.2 Exercise Can Improve the Functional Status of Autophagy in Brain with Nerve Damage -- 4.2 Exercise Can Improve AD Through Inducing Autophagy -- 4.2.1 Exercise Can Improve AD by Increasing the Activation of Autophagy -- 4.2.2 Exercise Can Improve AD by Enhancing the Degradation Function of Lysosomes. 4.2.3 Exercise Can Reduce the Deposition of AD-Like Aβ Through Autophagy -- 4.2.4 Exercise Can Reduce the Abnormal Phosphorylation of Tau by Improving Autophagy -- 4.2.5 Exercise Can Regulate Synaptic Plasticity Through Autophagy -- References -- Chapter 8: Exercise-Induced Autophagy and Parkinson´s Disease -- 1 Overview of Parkinson´s Disease (PD) -- 1.1 The Epidemiology of PD -- 1.2 The Pathogenesis of PD -- 1.3 Pathological Mechanisms of PD -- 1.3.1 Neuropathological Pathogenesis -- 1.3.2 Genetic Factors -- 1.3.3 Environmental Factors -- 1.3.4 Other Factors -- Immune Factors -- Oxidative Stress Factors -- 1.4 Current Status of Treatments -- 2 Autophagy Is Involved in PD -- 2.1 Mitophagy and PD -- 2.1.1 Parkinson´s Gene-Encoded Protein Is Involved in Mitochondrial Autophagy -- PTEN-Induced Kinase 1 (PINK1) and PARKIN Proteins Regulate Mitochondrial Autophagy -- DJ-1 Protein Regulates Mitochondrial Autophagy -- SNCA (Gene Encoding α-Synuclein) and α-Synuclein Regulate Mitochondrial Autophagy -- Leucine-Rich Repeat Kinase 2 (LRRK2) Regulates Mitochondrial Autophagy -- Glucocerebrosidase (GBA) Regulates Mitochondrial Autophagy -- ATPase Cation-Transporting 13A2 (ATP13A2) Regulates Mitochondrial Autophagy -- 2.1.2 Environmental Factors Regulate Mitochondrial Autophagy -- 2.2 The Relationship Between ALP and PD -- 2.3 The Role of microRNAs in PD -- 3 The Relationship Between Exercise and PD -- 3.1 Regulation of Exercise on Autophagy -- 3.2 The Regulatory Role of Exercise-Mediated Autophagy in PD -- References -- Chapter 9: Exercise-Mediated Autophagy in Cardiovascular Diseases -- 1 Introduction -- 2 Autophagy in Cardiovascular Diseases -- 3 Exercise-Mediated Autophagy in CVDs -- 3.1 Exercise-Mediated Autophagy in Hypertension -- 3.2 Exercise-Mediated Autophagy in Atherosclerosis -- 3.2.1 Autophagy and Atherosclerosis. 3.2.2 Exercise and Atherosclerosis -- 3.2.3 Effect of Exercise on Autophagy in Aorta -- 3.2.4 Exercise-Induced Autophagy Inhibits Atherosclerosis by Regulating Inflammatory Response and Lipid Metabolism -- 3.3 Exercise-Mediated Autophagy Alleviates Myocardial Ischemia-Reperfusion Injury -- 3.3.1 The Regulation of Autophagy During Ischemia -- 3.3.2 The Regulation of Autophagy During Reperfusion -- 3.3.3 Exercise Regulates Autophagy-Mediated Myocardial Ischemia-Reperfusion Injury -- 3.4 Exercise-Induced Autophagy in Cardioprotection -- 4 Conclusion -- References -- Chapter 10: Exercise-Induced Autophagy in the Prevention and Treatment of Sarcopenia -- 1 The Pathogenesis of Sarcopenia -- 2 The Regulation of Autophagy in Sarcopenia -- 2.1 ALS and UPS -- 2.2 Mitochondrial Quality Control -- 2.3 Satellite Cells -- 2.4 Inflammation -- 3 Exercise-Induced Autophagy Regulates Sarcopenia -- 3.1 Exercise and Sarcopenia -- 3.2 Exercise and Autophagy -- 3.3 Molecular Regulators of Exercise-Induced Autophagy -- 3.3.1 AMPK -- 3.3.2 PGC-1α -- 3.3.3 mTOR -- 3.3.4 FoxO -- 4 Exercise Advices -- 5 Conclusion -- References -- Chapter 11: Prospective Advances in Exercise-Induced Autophagy on Health -- 1 Introduction -- 2 Autophagy Pathways -- 3 Autophagy Is Activated During Exercise -- 4 Molecular Mechanisms of Exercise-Induced Autophagy -- 4.1 AMPK-mTOR-ULK1 Signal Pathway -- 4.2 Akt-mTOR Signal Pathway -- 4.3 Beclin1-Bcl-2 Complex -- 4.4 FoxO Family -- 4.5 Other Signal Pathways -- 5 Mitophagy -- 6 Exercise Adaptation for Health Promotion Through Induced Autophagy/Mitophagy -- 6.1 Exercise Performance -- 6.2 Skeletal Muscle Mass -- 6.3 Cardiovascular Adaptation -- 6.4 Glycolipid Metabolism Regulation -- 6.5 Mitochondrial Adaptation -- 6.6 Disease Status -- 7 Conclusion and Future Perspective -- References. Chapter 12: Exercise Mimetic Pills for Chronic Diseases Based on Autophagy. |
| Record Nr. | UNINA-9910502652503321 |
| Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The human microbiota and chronic disease : dysbioses as a cause of human pathology / / edited by Brian Henderson and Luigi Nibali
| The human microbiota and chronic disease : dysbioses as a cause of human pathology / / edited by Brian Henderson and Luigi Nibali |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Blackwell, , 2016 |
| Descrizione fisica | 1 online resource (563 p.) |
| Disciplina | 616.9/041 |
| Soggetto topico |
Human body - Microbiology
Chronic diseases Cos humà Microbiologia Malalties cròniques |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
1-118-98289-4
1-118-98288-6 1-118-98290-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910135041403321 |
| Hoboken, New Jersey : , : Wiley-Blackwell, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The human microbiota and chronic disease : dysbioses as a cause of human pathology / / edited by Brian Henderson and Luigi Nibali
| The human microbiota and chronic disease : dysbioses as a cause of human pathology / / edited by Brian Henderson and Luigi Nibali |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley-Blackwell, , 2016 |
| Descrizione fisica | 1 online resource (563 p.) |
| Disciplina | 616.9/041 |
| Soggetto topico |
Human body - Microbiology
Chronic diseases Cos humà Microbiologia Malalties cròniques |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
1-118-98289-4
1-118-98288-6 1-118-98290-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910820154603321 |
| Hoboken, New Jersey : , : Wiley-Blackwell, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
